학술논문
The Insulin-Only Bionic Pancreas Improves Glycemic Control in Non-Hispanic White and Minority Adults and Children With Type 1 Diabetes.
Document Type
Article
Author
Castellanos, Luz E.; Russell, Steven J.; Damiano, Edward R.; Beck, Roy W.; Shah, Viral N.; Bailey, Ryan; Calhoun, Peter; Bird, Keisha; Mauras, Nelly; Bionic Pancreas Research Group; Wadwa, R. Paul; Forlenza, Greg; Slover, Robert; Messer, Laurel; Cobry, Erin; Shah, Viral; Polsky, Sarit; Jost, Emily; Berget, Cari; Towers, Lindsey
Source
Subject
Language
ISSN
0149-5992
Abstract
OBJECTIVE: We evaluated the performance of the iLet bionic pancreas (BP) in non-Hispanic White individuals (here referred to as "Whites") and in Black, Hispanic, and other individuals (here collectively referred to as "Minorities"). RESEARCH DESIGN AND METHODS: A multicenter, randomized controlled trial evaluated glycemic management with the BP versus standard of care (SC) in 161 adult and 165 pediatric participants with type 1 diabetes over 13 weeks. RESULTS: In Whites (n = 240), the mean baseline-adjusted difference in 13-week HbA1c between the BP and SC groups was −0.45% (95% CI −0.61 to −0.29 [−4.9 mmol/mol; −6.6 to −3.1]; P < 0.001), while this difference among Minorities (n = 84) was −0.53% (−0.83 to −0.24 [−6.0 mmol/mol; −9.2 to −2.8]; P < 0.001). In Whites, the mean baseline-adjusted difference in time in range between the BP and SC groups was 10% (95% CI 7–12; P < 0.001) and in Minorities was 14% (10–18; P < 0.001). CONCLUSIONS: The BP improves glycemic control in both Whites and Minorities and offers promise in decreasing health care disparities. [ABSTRACT FROM AUTHOR]